QNTMHealthcare · Biotechnology

QNTM Stock Forecast: Quantum BioPharma Ltd. Price Predictions for 2026-2027

Last close, 4 Sept 2026

$3.24

+9.83% on the day

The 1 Wall Street analysts covering Quantum BioPharma Ltd. hold a median 12-month price target of $13 — +290.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 7 Sept 2026 — in the lower half.

Market cap

$20.8M

Ticker Nerd rank

43 / 100

Median analyst target

$13

Analysts covering

Revenue$0.0

Operating income−$2.3M

Net income−$3.1M

Free cash flow−$1.8M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+5.4%

+12.9%

YTD

−55.6%

−77.3%

From 52W high

−83.8%

From 52W low

+54.3%

$20

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

QNTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quantum BioPharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026

43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance

Size

Growth

Accruals

Quality

Revisions

Volatility

Value

Momentum

Issuance (87): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QNTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QNTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $13Median $13High $13

The green dot is the last close — the median target sits +290.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
31 Aug 2026	Rodman & Renshaw	Initiates	Buy	$8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNTM appears on the weeks it earns a place.

Performance

QNTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Quantum BioPharma Ltd. returned −77.3% against +20.0% for the S&P 500, dividends included.

QNTM vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QNTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Quantum BioPharma Ltd. (QNTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.4×
Price / sales: —
Price / book: 3.1×
EV / EBITDA: −1.8×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −621.5%
Return on assets: −51.8%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Quantum BioPharma Ltd. (QNTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Quantum BioPharma Ltd. has a market value of $20.8M and an enterprise value of $21.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$25.3M.
Free cash flow in the twelve months to 30 June 2026: −$5.5M.
Shares outstanding: 7.6M.
Trailing P/E: −0.4×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Quantum BioPharma Ltd. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

QNTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
QNTMQuantum BioPharma Ltd.	$20.8M	43
TCRXTScan Therapeutics, Inc.	$25.6M	40
TVRDTvardi Therapeutics, Inc.	$25.5M	29
BYSIBeyondSpring, Inc.	$25.4M	18
ESLAEstrella Immunopharma, Inc.	$27.2M	25
ATOSAtossa Therapeutics, Inc.	$25.1M	24
ABVCABVC BioPharma, Inc.	$24.4M	12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quantum BioPharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QNTM news & analysis

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

GlobeNewsWire · 1 Sept 2026negative

Quantum BioPharma has announced plans to voluntarily delist its Class B shares from the Canadian Securities Exchange. The news release is intended for distribution in Canada only and not for dissemination in the United States.

Why it matters — A voluntary delisting from the CSE is a significant corporate action that could affect the trading venue and accessibility of Quantum BioPharma's Class B shares for investors.

Quantum Biopharma Provides Corporate Update

GlobeNewsWire · 21 Aug 2026neutral

Quantum BioPharma issued a corporate update via GlobeNewsWire. The release is intended for distribution in Canada only and is not intended for distribution in the United States.

Why it matters — A QNTM watcher would care because the update provides official corporate information, though its distribution is limited to Canada.

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

GlobeNewsWire · 14 Aug 2026positive

Quantum BioPharma reported its second-quarter 2026 financial and operational results, ended June 30, 2026, saying it strengthened its equity and liquidity. The FDA approved Lucid-MS for a pivotal Phase 2 clinical trial.

Why it matters — QNTM watchers would care because FDA approval to advance Lucid-MS into a pivotal Phase 2 trial is a key clinical milestone for the company's pipeline, alongside its reported improvements in equity and liquidity.

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

GlobeNewsWire · 10 Aug 2026positive

Quantum BioPharma announced that the U.S. FDA has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), a patented first-in-class neuroprotective therapy targeting demyelination. This clearance enables the company to begin a randomized, double-blind, placebo-controlled Phase 2 clinical trial in progressive multiple sclerosis.

Why it matters — FDA clearance to advance Lucid-MS into Phase 2 represents a significant regulatory milestone for Quantum BioPharma's lead multiple sclerosis program, moving its novel disease-modifying candidate closer to addressing a progressive MS market with substantial unmet medical need.

Quantum BioPharma Announces Closing of Debt Settlement

GlobeNewsWire · 30 July 2026positive

Quantum BioPharma Ltd. announced the closing of a debt settlement, according to a press release intended for distribution in Canada only.

Why it matters — Closing a debt settlement can improve Quantum BioPharma's balance sheet by resolving outstanding liabilities, which shareholders may view as a step toward financial stability.

FAQ

Frequently asked questions about QNTM stock

What is the QNTM stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Quantum BioPharma Ltd. have a median 12-month price target of $13, with estimates ranging from $13 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QNTM stock a buy right now?

Of the 1 analysts covering Quantum BioPharma Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum BioPharma Ltd. 43 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QNTM?

As at 7 Sept 2026, Quantum BioPharma Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (87 of 100).

Will QNTM stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +290.0% from the last close, and Ticker Nerd's factor model ranks Quantum BioPharma Ltd. 43 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QNTM stock forecast for 2030?

No analyst covering Quantum BioPharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $13 over the next 12 months.

How has QNTM stock performed over the past year?

Quantum BioPharma Ltd. returned -77.3% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quantum BioPharma Ltd. do?

What is the latest news on QNTM?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange". Quantum BioPharma has announced plans to voluntarily delist its Class B shares from the Canadian Securities Exchange. The news release is intended for distribution in Canada only and not for dissemination in the United States.

Company

About Quantum BioPharma Ltd.

Quantum BioPharma Ltd. Class B Subordinate Voting Shares represents the equity interest in Quantum BioPharma Ltd., a Toronto-based biopharmaceutical company focused on developing and advancing biotech solutions for challenging neurodegenerative, metabolic, inflammatory, and alcohol misuse disorders. The company’s current activities center on a portfolio of drug candidates and related life sciences assets across its biopharmaceutical and strategic investments segments. Its Class B shares provide exposure to a company operating in specialty therapeutics and biomedical innovation, with a structure that includes subordinate voting rights relative to the company’s Class A multiple voting shares. Quantum BioPharma Ltd. serves institutional and retail market participants interested in the life sciences sector, where clinical development, intellectual property, and asset portfolio management are key parts of the business model.

CEO Mr. Zeeshan Saeed · 17 employees · Canada · https://www.quantumbiopharma.com